Primary Open Angle Glaucoma, Primary Angle Closure Glaucoma, Normal Tension Glaucoma, Ocular Hypertension
Conditions
Interventions
one cohort:Colorless clear 0.0015% aqueous ophthalmic solution containing 15 ug of tafluprost in 1 ml One drop is instilled to the affected eye(s), once daily (same as the approved dosage) for one mon
Sponsors
Santen Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed with primary open angle glaucoma (POAG), primary angle closure glaucoma (PACG), normal tension glaucoma (NTG) or ocular hypertension (OHT); 2) Switching from latanoprost (other concomitant drugs should not be changed 1 month prior to the switch of medication and are continued during the treatment period); 3) Age between 18 to 70 years; 4) Those who can visit the clinic on the designated day as instructed by the physician.
Exclusion criteria
Exclusion criteria: 1) History of intraocular surgery or laser treatment during the three months before informed consent; 2) History of corneal refractive surgery; 3) History of drug allergy (hypersensitivity) to the drugs to be used during the study period (anesthetic ophthalmic solution, fluorescein, etc.) or similar drugs to the investigational product; 4) Presence of any corneal disorder that may interfere with accurate IOP measurement using applanation tonometer; 5) Female patients who are pregnant, nursing or planning a pregnancy; 6) Patients who need to change their pretreating ophthalmic medications (other than latanoprost) during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the adverse effect profile of tafluprost to latanoprost; | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the IOP - lowering effect of tafluprost to latanoprost.; | — |
Countries
China
Contacts
Public ContactProf. Tham Chee-yung, Clement
Outcome results
None listed